Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/004287COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER
WO 26.01.2023
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No PCT/US2022/073845 Applicant REGENERON PHARMACEUTICALS, INC. Inventor DADI-MEHMETAJ, Saida
This disclosure relates to novel triple combination therapies of an oncolytic virus, a PD-1 pathway inhibitor, and a CTLA4 inhibitor for treating or inhibiting the growth of a tumor in a patient with cancer.
2.4122478COMPOSITIONS AND METHODS OF USING STAT1/3 INHIBITORS WITH ONCOLYTIC HERPES VIRUS
EP 25.01.2023
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 22180454 Applicant VIROGIN BIOTECH CANADA LTD Inventor JIA WILLIAM
The present disclosure relates to the use of an oncolytic virus, such as HSV, and a STAT1/3 inhibitor, such as nifuroxazide and C16, in the treatment of cancer. Therapeutic compositions are provided that may be used to prevent, treat, or ameliorate the effects of a targeted cancer. Methods of using such compositions are also disclosed, such as methods of using the therapeutic compositions for improving efficacy of an oncolytic virotherapy (and for preventing macrophage and microglia inhibition of oncolytic viral activity).
3.WO/2023/288334METHOD OF TREATING DRUG RESISTANT ESKAPE PATHOGENS USING THERAPEUTIC BACTERIOPHAGES
WO 19.01.2023
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2022/073852 Applicant THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY Inventor FILIPPOV, Andrey
A method of improving an immunological response in a human subject suffering from a Pseudomonas aeruginosa in a wound comprising the step of: (i) administering one or more isolated and purified strains of Pseudomonas aeruginosa and one or more pharmaceutically acceptable carriers or adjuvants to the wounded area of the human subject, said genomic phages interacting with innate and adaptive immune system of the human subject, while providing biological protection and/or wound recovery or stimulation; and (ii) co-administering one or more additional genomic phages selected from genomic phages selected from Myoviridae, Podoviridae and Siphoviridae interacts and one or more pharmaceutically acceptable carriers or adjuvants to the wounded area of the human subject.
4.WO/2023/288135GENE EDITING TO IMPROVE JOINT FUNCTION
WO 19.01.2023
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/US2022/037490 Applicant ORTHOBIO THERAPEUTICS, INC. Inventor GENTSCH, George
Treatment of osteoarthritis, degenerative joint disease, and other joint dysfunction is complex and there are few long term options for either symptomatic relief or restoring joint function. The present disclosure provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritis and to treat osteoarthritis and other arthritis in a mammalian joint.
5.20230015373Composition comprising amino acid polymers and a bioactive agent and method of preparing thereof
US 19.01.2023
Int.Class A61K 9/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
70Web, sheet or filament bases
Appl.No 17813871 Applicant PHAGELUX (CANADA) INC. Inventor Nancy Tawil

A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

6.WO/2023/284597COMBINED THERAPY FOR TREATING CANCER
WO 19.01.2023
Int.Class A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Appl.No PCT/CN2022/104040 Applicant ADLAI NORTYE BIOPHARMA CO., LTD. Inventor HE, Nanhai
The present application provides a method for treating a tumor/cancer and/or generating a memory immune response against a tumor/cancer in a subject in such a need, comprising administering to the subject an effective amount of a PI3K inhibitor, an oncolytic virus, and a PD-1 inhibitor, wherein the PI3K inhibitor, the oncolytic virus, and the PD-1 inhibitor can be simultaneously, separately, or sequentially administered. The present application further provides a pharmaceutical composition comprising a PI3K inhibitor, an oncolytic virus, a PD-1 inhibitor, and a pharmaceutically acceptable carrier, and a medicine box comprising the pharmaceutical composition and use description.
7.20230017360KIT FOR PREPARING NANOPARTICLE COMPOSITION FOR DRUG DELIVERY
US 19.01.2023
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
Appl.No 17778655 Applicant SAMYANG HOLDINGS CORPORATION Inventor So Jin LEE

The present invention relates to a kit for preparing a nanoparticle composition for drug delivery and, more specifically, to a kit for preparing a nanoparticle composition for drug wherein the kit is designed such that the kit does not comprise a polylactic acid salt and nanoparticles containing a drug encapsulated therein can be easily formed just by simply mixing an amphiphilic block copolymer, a cationic compound, and a drug as components of the kit.

8.2023500996遺伝子導入による眼色の変更
JP 17.01.2023
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 2022543406 Applicant ヒル, ジェイムズ ダブリュー. Inventor ヒル, ジェイムズ ダブリュー.
人の虹彩の色は、人の眼の角膜を通して殺メラノサイト剤を導入し、虹彩の前面を、虹彩ストローマ内のメラノサイトを死滅させるために十分な用量でその薬剤と接触させることによって、明るくする、例えば、ブラウンから、より明るいブラウン、グリーン、ヘーゼル、またはブルーにすることができる。一態様において、本開示は、(a)自殺遺伝子;および(b)前記自殺遺伝子に作動可能に連結されているメラノサイト特異的遺伝子プロモーターを保持する遺伝子ベクターを含む滅菌点眼調製物を含む、対象の虹彩の色を変更するための組成物を提供する。
9.2021120556Способ лечения или профилактики рецидивов нозокомиальной пневмонии
RU 13.01.2023
Int.Class A61P 31/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
Appl.No 2021120556 Applicant Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии и Реабилитологии" (ФНКЦ РР) (RU) Inventor Белобородова Наталья Владимировна (RU)
10.WO/2023/280791METHOD FOR PRODUCING BACTERIOPHAGES
WO 12.01.2023
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2022/068487 Applicant VESALE BIOSCIENCE Inventor QUINTENS, Johan
The invention relates to a method for producing bacteriophages, which comprises: providing at least one cell culture chamber; providing a first vessel containing a culture medium in a first closed-circuit connection with said at least one cell culture chamber, the culture medium comprising at least one strain of phages and at least one strain of bacteria; transferring the culture medium from the first vessel via the first closed-circuit connection into said at least one cell culture chamber in order to deposit the culture medium as a culture layer in said at least one culture chamber; incubating the culture medium so as to propagate phages; providing a container in a second closed-circuit connection with said at least one cell culture chamber, the second closed-circuit connection comprising a filtration system between said at least one cell culture chamber and the container; and transferring the culture medium comprising the propagated phages from said at least one culture chamber to the second closed-circuit connection and purifying said propagated phages via the filtration system, the culture medium being in liquid form during the transfer from said at least one culture chamber to the second closed-circuit connection and during the purification.